CN113318072A - Compound realgar ointment for treating herpes zoster and preparation method thereof - Google Patents
Compound realgar ointment for treating herpes zoster and preparation method thereof Download PDFInfo
- Publication number
- CN113318072A CN113318072A CN202110763769.9A CN202110763769A CN113318072A CN 113318072 A CN113318072 A CN 113318072A CN 202110763769 A CN202110763769 A CN 202110763769A CN 113318072 A CN113318072 A CN 113318072A
- Authority
- CN
- China
- Prior art keywords
- weight percentage
- realgar
- ointment
- compound
- percentage content
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052957 realgar Inorganic materials 0.000 title claims abstract description 126
- 239000002674 ointment Substances 0.000 title claims abstract description 78
- 150000001875 compounds Chemical class 0.000 title claims abstract description 74
- 208000007514 Herpes zoster Diseases 0.000 title claims abstract description 46
- 238000002360 preparation method Methods 0.000 title claims abstract description 45
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 76
- 239000003814 drug Substances 0.000 claims abstract description 56
- 229940079593 drug Drugs 0.000 claims abstract description 43
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 36
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 35
- 229940116229 borneol Drugs 0.000 claims abstract description 35
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 35
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 35
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims abstract description 26
- 238000000034 method Methods 0.000 claims abstract description 14
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229940075507 glyceryl monostearate Drugs 0.000 claims abstract description 13
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims abstract description 13
- 229920001993 poloxamer 188 Polymers 0.000 claims abstract description 13
- 229940044519 poloxamer 188 Drugs 0.000 claims abstract description 13
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims abstract description 13
- 229920000053 polysorbate 80 Polymers 0.000 claims abstract description 13
- 241000700605 Viruses Species 0.000 claims abstract description 7
- 239000004094 surface-active agent Substances 0.000 claims abstract description 4
- 238000010008 shearing Methods 0.000 claims abstract description 3
- 239000012071 phase Substances 0.000 claims description 128
- 239000011159 matrix material Substances 0.000 claims description 32
- 238000003756 stirring Methods 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 19
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 18
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 claims description 12
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 12
- 239000008346 aqueous phase Substances 0.000 claims description 10
- 238000001816 cooling Methods 0.000 claims description 10
- 229940067866 dandelion extract Drugs 0.000 claims description 10
- 235000020691 dandelion extract Nutrition 0.000 claims description 10
- 239000002994 raw material Substances 0.000 claims description 10
- 239000001845 taraxacum officinale leaf extract Substances 0.000 claims description 10
- 229940064064 purslane extract Drugs 0.000 claims description 9
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 8
- 235000001855 Portulaca oleracea Nutrition 0.000 claims description 6
- 241000219304 Portulacaceae Species 0.000 claims description 6
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 6
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims description 6
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims description 6
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 6
- 229960003639 laurocapram Drugs 0.000 claims description 6
- 229940057995 liquid paraffin Drugs 0.000 claims description 6
- 229940099259 vaseline Drugs 0.000 claims description 6
- 241000245665 Taraxacum Species 0.000 claims description 5
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims description 5
- 239000006071 cream Substances 0.000 claims description 3
- 229960000541 cetyl alcohol Drugs 0.000 claims description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 2
- 229940012831 stearyl alcohol Drugs 0.000 claims description 2
- 239000000758 substrate Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 24
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 2
- 238000003672 processing method Methods 0.000 abstract 1
- 238000011156 evaluation Methods 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000002131 composite material Substances 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 229940040145 liniment Drugs 0.000 description 4
- 239000000865 liniment Substances 0.000 description 4
- 210000000582 semen Anatomy 0.000 description 4
- 239000006210 lotion Substances 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 241001057584 Myrrha Species 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 229940126678 chinese medicines Drugs 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000000091 immunopotentiator Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229940100615 topical ointment Drugs 0.000 description 2
- 229940126673 western medicines Drugs 0.000 description 2
- 241000205585 Aquilegia canadensis Species 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000717739 Boswellia sacra Species 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N Calcium oxide Chemical compound [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- 241001161070 Calomela Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000035126 Facies Diseases 0.000 description 1
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 description 1
- 239000004863 Frankincense Substances 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 235000006753 Platycodon grandiflorum Nutrition 0.000 description 1
- 240000003582 Platycodon grandiflorus Species 0.000 description 1
- 244000299790 Rheum rhabarbarum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- 241000207929 Scutellaria Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 description 1
- OPXFZJLGAZHBMA-UHFFFAOYSA-N [[1-(carbamothioylhydrazinylidene)-3-(1,3-dioxoisoindol-2-yl)butan-2-ylidene]amino]thiourea Chemical compound C1=CC=C2C(=O)N(C(C)C(C=NNC(N)=S)=NNC(N)=S)C(=O)C2=C1 OPXFZJLGAZHBMA-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000003088 amphibian venom Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 229960000785 fluocinonide Drugs 0.000 description 1
- 229910052602 gypsum Inorganic materials 0.000 description 1
- 239000010440 gypsum Substances 0.000 description 1
- 239000008309 hydrophilic cream Substances 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- RSIJVJUOQBWMIM-UHFFFAOYSA-L sodium sulfate decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[O-]S([O-])(=O)=O RSIJVJUOQBWMIM-UHFFFAOYSA-L 0.000 description 1
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940093257 valacyclovir Drugs 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 229940045860 white wax Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/36—Arsenic; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Communicable Diseases (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention belongs to the field of pharmaceutical preparations, and particularly relates to compound realgar ointment for treating herpes zoster and a preparation method thereof. The compound realgar ointment is an oil-in-water type emulsifiable paste and consists of an oil phase, a water phase and a main drug; the oil phase contains a surfactant, glyceryl monostearate; the water phase contains herba Taraxaci extract, herba Portulacae extract, tween 80 and poloxamer 188; the main drugs are realgar and borneol. The preparation method of the compound realgar ointment comprises the step of preparing the oil phase, the water phase and the main drug into the compound realgar ointment by a high-speed shearing method. The compound realgar ointment prepared by the invention has the characteristics of simple processing method, high storage stability, obvious herpes zoster virus resistant effect and the like.
Description
Technical Field
The invention belongs to the field of pharmaceutical preparations, and particularly relates to compound realgar ointment for treating herpes zoster and a preparation method thereof.
Background
Herpes zoster is commonly called as herpes zoster, is an acute skin mucosal infectious disease caused by herpes zoster virus, is clinically manifested by herpes which is suddenly generated, distributed along nerve bands, unilaterally distributed and densely grouped, and has obvious pain. The incidence rate of herpes zoster in adults is about 10% -20%, and herpes zoster is a common skin disease which is common to the elderly and people with immunodeficiency.
At present, the treatment of herpes zoster is mainly drug therapy, and can be divided into antiviral drugs, immunopotentiators, local treatment drugs and the like according to different action principles. Antiviral drugs such as acyclovir, valaciclovir and the like are commonly used, and the drugs have certain toxic and side effects; immunopotentiators have a slow onset of action against herpes zoster, and many preparations are still under study and cannot be used on a large scale; the topical medicine mainly comprises topical disinfectant such as idodine and ftibamzone, which can relieve inflammatory red swelling of affected part and pain of patient, but can not cure diseases radically. Therefore, the search for new drugs for treating herpes zoster is very important.
The traditional Chinese medicine understanding of herpes zoster originates from Song front, matures in Ming Qing and perfects on near modern times, and the people with retort sores appear in the Chao generation nest-original theory of diseases and symptoms and are induced around the waist. It is also known as retort strip, because it is generated by the blood and qi of the wind-damp attacking, the "retort strip sores" are the earliest record of herpes zoster. The externally applied traditional Chinese medicine has remarkable advantages in the treatment of herpes zoster, realgar is favored due to good effect on herpes zoster, the use of realgar in the treatment of herpes zoster has a long history, and the use of realgar in all medical books of ancient generations such as "effective prescription of medicine", Ming dynasty Wangkong Tang "registration of treatment of syndrome, Qing dynasty Bao facies " new edition of proved prescription "and the like can effectively treat herpes zoster. Realgar as an ore medicine has many limitations in use due to its strong hydrophobicity. The method recorded in the medical books of past generations only utilizes the method of levigating to grind into fine powder, and the fine powder is externally used or taken together with other medicines, so the development of a new realgar preparation by utilizing the modern technology becomes one of the keys for exerting the curative effect of the realgar preparation.
At present, the authorized and published realgar-containing external herpes zoster preparations almost adopt compound combined medicines, and the dosage forms of lotion, medicated wine, liniment, ointment and the like are also selected, so that the problems of complex preparation and inconvenient use are widely existed. For example, Chinese patent CN108295142B, "a Chinese medicinal formula lotion for treating herpes zoster", is prepared by decocting Realgar, calx, dried fructus Zanthoxyli, fresh herba Artemisiae Annuae, and fresh herba Houttuyniae to obtain topical abrasive lotion, which is decocted by itself during application and is inconvenient; chinese patent CN112121106A "A Liniment for external use for treating herpes zoster and its preparation method" adopts ten kinds of medicinal materials such as tobacco leaf, radix Sophorae Flavescentis, Coptidis rhizoma, semen Celosiae, Concha Haliotidis, rhizoma Nardostachyos, Myrrha, radix Saposhnikoviae, Notopterygii rhizoma and Realgar powder etc. to prepare the Liniment for external use by decocting with water, not only the preparation process is tedious, but also the prepared Liniment can not be preserved for a long time; chinese patent CN112402508A "A Chinese medicinal composition for treating herpes zoster and its preparation method" adopts Coptidis rhizoma, Scutellariae radix, cortex Phellodendri, radix et rhizoma Rhei, semen Strychni, Borneolum Syntheticum, Olibanum, Myrrha, and Realgar as formula, and medical alcohol as solvent to prepare medicated liquor, which has great harm to skin and is difficult for patients to adapt during treatment; chinese patent CN106913643A A Realgar ointment and its preparation method, comprises semen Armeniacae amarum, Realgar, semen Benincasae, radix Angelicae Dahuricae, and herba Lysimachiae foenumgraeci, and is prepared into ointment by white wax and oleum Sesami, and the ointment prepared by the method has large oiliness, inconvenient use, and poor skin feeling.
In addition, some patents use the method of directly applying the medicine powder or the mode of combining Chinese and western medicines for treatment, for example, Chinese patent CN110115726A, "an external application medicine for treating herpes zoster" uses 9 medicines of bear gall powder, realgar, toad venom, rhubarb, balloon flower, gypsum, scutellaria, honeysuckle and borneol, and grinds the medicines into powder, and when in use, the medicine is mixed into paste by old vinegar and applied to the affected part, thus the steps are complicated, the dosage is difficult to control, and the tolerance of the patient is not good; chinese patent CN103816181A 'A topical ointment containing Chinese and western medicines for treating herpes zoster and its preparation method' adopts Realgar, Sulfur, Lithargyrum, Calomelas, Natrii sulfas, compound acetylsalicylic acid powder, Metronidazole powder, fluocinonide cream to prepare topical ointment.
Disclosure of Invention
Aiming at the problems in the prior art, the invention aims to overcome the defects of the existing realgar-containing herpes zoster preparation for external use, and provides a realgar-containing compound ointment and a preparation method thereof.
A compound realgar ointment for treating herpes zoster is characterized in that the compound realgar ointment is an oil-in-water type cream and consists of an oil phase, a water phase and a main drug; the oil phase contains a surfactant, glyceryl monostearate; the water phase contains herba Taraxaci extract, herba Portulacae extract, tween 80 and poloxamer 188; the main drugs are realgar and borneol.
Further, the oil phase accounts for 35-50% of the compound realgar ointment, the water phase accounts for 40-60% of the compound realgar ointment, and the main drug accounts for 5-20% of the compound realgar ointment. Preferably, the oil phase accounts for 40-45% of the compound realgar ointment, the water phase accounts for 45-55% of the compound realgar ointment, and the main drug accounts for 10-15% of the compound realgar ointment.
Further, in the compound realgar ointment, the weight percentage content of the glyceryl monostearate is 1.0-4.0%, the weight percentage content of the dandelion extract is 0.5-2.5%, the weight percentage content of the purslane extract is 0.5-2.5%, the weight percentage content of the tween 80 is 2.0-5.0%, the weight percentage content of the poloxamer 188 is 0.1-1.0%, the weight percentage content of the realgar is 5.0-15.0%, and the weight percentage content of the borneol is 0.5-1.5%. Preferably, the weight percentage content of the glyceryl monostearate is 2.0-3.0%, the weight percentage content of the dandelion extract is 1.0-2.0%, the weight percentage content of the purslane extract is 1.0-2.0%, the weight percentage content of the tween 80 is 3.0-4.0%, the weight percentage content of the poloxamer 188 is 0.2-0.5%, the weight percentage content of the realgar is 8.0-12.0%, and the weight percentage content of the borneol is 0.8-1.2%.
Further, the compound realgar ointment consists of an oil phase, a water phase and a main drug; the oil phase contains vaseline, liquid paraffin, cetyl alcohol, stearyl alcohol, glyceryl monostearate and Azone (oil soluble laurocapram); the water phase contains herba Taraxaci extract, herba Portulacae extract, glycerol, Tween 80, poloxamer 188 and ethylparaben; the main drugs are realgar and borneol.
Further, in the compound realgar ointment, the weight percentage of the vaseline is 5.0-15.0%, the weight percentage of the liquid paraffin is 10.0-20.0%, the weight percentage of the hexadecanol is 5.0-15.0%, the weight percentage of the octadecanol is 5.0-15.0%, the weight percentage of the glyceryl monostearate is 1.0-4.0%, and the weight percentage of the Azone (oil-soluble laurocapram) is 0.5-2.5%; the weight percentage content of the dandelion extract is 0.5-2.5%, the weight percentage content of the purslane extract is 0.5-2.5%, the weight percentage content of the glycerol is 1.5-10.0%, the weight percentage content of the tween 80 is 2.0-5.0%, the weight percentage content of the poloxamer 188 is 0.1-1.0%, and the weight percentage content of the ethylparaben is 0-0.5%; the weight percentage content of the realgar is 5.0-15.0 percent, and the weight percentage content of the borneol is 0.5-1.5 percent.
Preferably, in the compound realgar ointment, the weight percentage of the vaseline is 7.0-12.0%, the weight percentage of the liquid paraffin is 12.0-15.0%, the weight percentage of the hexadecanol is 8.0-12.0%, the weight percentage of the octadecanol is 8.0-12.0%, the weight percentage of the glyceryl monostearate is 2.0-3.0%, and the weight percentage of the Azone (oil-soluble laurocapram) is 1.0-2.0%; 1.0-2.0% of dandelion extract, 1.0-2.0% of purslane extract, 2.5-5.0% of glycerol, 3.0-4.0% of tween 80, 0.2-0.5% of poloxamer 188 and 0.1-0.3% of ethylparaben; the weight percentage content of the realgar is 8.0-12.0 percent, and the weight percentage content of the borneol is 0.8-1.2 percent.
Further, the compound realgar ointment comprises the following raw materials in percentage by weight:
a oil phase
B aqueous phase
Principal drug C
10 percent of realgar
1 percent of borneol.
The invention also provides a preparation method of the compound realgar ointment, which comprises the step of preparing the compound realgar ointment from the oil phase, the water phase and the main drug through a high-speed shearing method.
Further, the preparation method comprises the following steps:
(1) preparing a matrix: placing the oil phase A and the water phase B in a water bath at 90 ℃ until the oil phase A and the water phase B are completely dissolved, taking out the oil phase C, slowly pouring the water phase into the oil phase when the temperature of the oil phase is slightly lower than that of the water phase, stirring continuously, adding borneol when the substrate starts to be emulsified, and continuously stirring until the mixture is completely emulsified;
(2) cooling matrix to room temperature, adding Realgar by 3 times, and stirring.
Further, in the compound realgar ointment, the dandelion extract is prepared by a decoction method: taking 200g of dandelion, adding 800g of water, and decocting with slow fire to 200 mL.
Further, in the compound realgar ointment, the purslane extract is prepared by a decoction method: 200g of purslane is taken, 800g of water is added, and the mixture is decocted to 200mL by slow fire.
The invention also provides application of the compound realgar ointment in preparing medicaments for killing herpes zoster viruses and treating herpes zoster.
Has the advantages that:
the invention redesigns the medicine aiming at the defects of the prior realgar-containing herpes zoster preparation for external use. The realgar and borneol are taken as main medicines, and the purslane and dandelion are taken as auxiliary medicines, so that the composition of the prescription is greatly simplified, and the most popular ointment formulation for external use is selected in the formulation. Due to the strong hydrophobicity of realgar and the characteristics of herpes zoster, the oil-in-water cream is selected as the ointment matrix, and three surfactants are adopted for compounding according to the medicine composition, so that the optimal matrix composition is screened out; meanwhile, effective components of purslane and dandelion in the formula are extracted, and the formula of the preparation is further optimized, so that the purslane and dandelion can better play a role in treatment. The prepared preparation has the characteristics of simple processing, low production cost and high preparation stability, and clinical tests prove that the preparation has the characteristics of obvious herpes zoster virus resistant effect, safe use, high patient acceptance and the like.
The prescription of the invention has simple formula, novel formula composition and high acceptance to patients, can be produced in large scale and has safer production process; the oil-in-water emulsifiable paste matrix in the preparation can uniformly disperse the realgar, so that a patient can conveniently and automatically apply the realgar to an affected part, the acceptance degree of the patient is greatly increased, meanwhile, the highly dispersed realgar is tightly combined with the affected part, the activity of killing herpes zoster viruses is high, the effectiveness of the preparation is greatly improved, and the preparation meets the target of modern Chinese medicine external application.
Drawings
Fig. 1 shows the first preparation of compound realgar ointment.
Fig. 2 shows the finished product of the compound realgar ointment after packaging.
FIG. 3(a) is a photograph of an untreated affected part of a patient with herpes zoster; fig. 3(b) is a photograph of the affected part of a patient with herpes zoster after using the compound realgar ointment (example 1) of the invention for three days. Shows that the virus is obviously inhibited at the affected part and has good clinical use effect.
Detailed Description
The present invention will be described in further detail with reference to specific embodiments. It should be emphasized that: the following description is merely exemplary in nature and is in no way intended to limit the scope of the invention or its application.
The application method of the compound realgar ointment comprises the following steps: the affected part is treated to be clean and dry, the compound realgar ointment prepared in the embodiment is uniformly smeared on the affected part, and the compound realgar ointment is used for three days, wherein the dosage is suitable for completely covering the affected part, and the compound realgar ointment is used once a day.
The evaluation method comprises the following steps: the stability (good, not good), viscosity (large, proper, small), spreadability (good, not good), and skin adhesion (good, not good) of the compound realgar ointment prepared in each example, as well as the treatment effect (good, not good) and the patient acceptance (high, normal, low) were evaluated.
Example 1
A compound realgar ointment for treating herpes zoster and a preparation method thereof, the preparation method comprises the following steps:
the composite material comprises the following raw materials in percentage by weight:
a oil phase
B aqueous phase
Principal drug C
10 percent of realgar
1 percent of borneol.
(1) Preparing a matrix: placing the oil phase A and the water phase B in a water bath at 90 ℃ until the oil phase A and the water phase B are completely dissolved, taking out the oil phase A, slowly pouring the water phase B into the oil phase A when the temperature of the oil phase A is slightly lower than that of the water phase B, stirring continuously, adding the borneol serving as the main drug C when the matrix starts to emulsify, and continuously stirring until the mixture is completely emulsified;
(2) cooling matrix to room temperature, adding Realgar as principal agent C for 3 times, and stirring.
Prescription and treatment effect evaluation: the compound realgar ointment prepared by the prescription has good stability, proper viscosity, good spreadability and good skin adhesiveness; the clinical use effect is good, and the patient acceptance is high.
Example 2:
a compound realgar ointment for treating herpes zoster and a preparation method thereof, the preparation method comprises the following steps:
the composite material comprises the following raw materials in percentage by weight:
a oil phase
B aqueous phase
Principal drug C
12 percent of realgar
1 percent of borneol.
(1) Preparing a matrix: placing the oil phase A and the water phase B in a water bath at 90 ℃ until the oil phase A and the water phase B are completely dissolved, taking out the oil phase A, slowly pouring the water phase B into the oil phase A when the temperature of the oil phase A is slightly lower than that of the water phase B, stirring continuously, adding the borneol serving as the main drug C when the matrix starts to emulsify, and continuously stirring until the mixture is completely emulsified;
(2) cooling matrix to room temperature, adding Realgar as principal agent C for 3 times, and stirring.
Prescription and treatment effect evaluation: the compound realgar ointment prepared by the prescription has good stability, high viscosity, poor spreadability and good skin adhesiveness; the clinical use effect is better, but the patient acceptance is general.
Example 3:
a compound realgar ointment for treating herpes zoster and a preparation method thereof, the preparation method comprises the following steps:
the composite material comprises the following raw materials in percentage by weight:
a oil phase
B aqueous phase
Principal drug C
8 percent of realgar
1.5 percent of borneol.
(1) Preparing a matrix: placing the oil phase A and the water phase B in a water bath at 80 ℃ until the oil phase A and the water phase B are completely dissolved, taking out the oil phase A, slowly pouring the water phase B into the oil phase A when the temperature of the oil phase A is slightly lower than that of the water phase B, stirring continuously, adding the borneol serving as the main drug C when the matrix starts to emulsify, and continuously stirring until the mixture is completely emulsified;
(2) cooling matrix to room temperature, adding Realgar as principal agent C for 3 times, and stirring.
Prescription and treatment effect evaluation: the compound realgar ointment prepared by the prescription has good stability, low viscosity, good spreadability and poor skin adhesiveness; the clinical use effect is good, but the patient acceptance is general.
Example 4:
a compound realgar ointment for treating herpes zoster and a preparation method thereof, the preparation method comprises the following steps:
the composite material comprises the following raw materials in percentage by weight:
a oil phase
B aqueous phase
Principal drug C
11 percent of realgar
3 percent of borneol.
(1) Preparing a matrix: placing the oil phase A and the water phase B in a water bath at 85 ℃ until the oil phase A and the water phase B are completely dissolved, taking out the oil phase A, slowly pouring the water phase B into the oil phase A when the temperature of the oil phase A is slightly lower than that of the water phase B, stirring continuously, adding the borneol serving as the main drug C when the matrix starts to emulsify, and continuously stirring until the mixture is completely emulsified;
(2) cooling matrix to room temperature, adding Realgar as principal agent C for 3 times, and stirring.
Prescription and treatment effect evaluation: the compound realgar ointment prepared by the prescription has good stability, high viscosity, good spreadability and good skin adhesiveness; the clinical use effect is better, and the patient acceptance is general.
Example 5:
a compound realgar ointment for treating herpes zoster and a preparation method thereof, the preparation method comprises the following steps:
the composite material comprises the following raw materials in percentage by weight:
a oil phase
B aqueous phase
Principal drug C
10 percent of realgar
1 percent of borneol.
(1) Preparing a matrix: placing the oil phase A and the water phase B in a water bath at 90 ℃ until the oil phase A and the water phase B are completely dissolved, taking out the oil phase A, slowly pouring the water phase B into the oil phase A when the temperature of the oil phase A is slightly lower than that of the water phase B, stirring continuously, adding the borneol serving as the main drug C when the matrix starts to emulsify, and continuously stirring until the mixture is completely emulsified;
(2) cooling matrix to room temperature, adding Realgar as principal agent C for 3 times, and stirring.
Prescription and treatment effect evaluation: the compound realgar ointment prepared by the prescription has good stability, high viscosity, good spreadability and good skin adhesiveness; the clinical use effect is good, and the patient acceptance is general.
Example 6:
a compound realgar ointment for treating herpes zoster and a preparation method thereof, the preparation method comprises the following steps:
the composite material comprises the following raw materials in percentage by weight:
a oil phase
B aqueous phase
Principal drug C
10 percent of realgar
1 percent of borneol.
(1) Preparing a matrix: placing the oil phase A and the water phase B in a water bath at 90 ℃ until the oil phase A and the water phase B are completely dissolved, taking out the oil phase A, slowly pouring the water phase B into the oil phase A when the temperature of the oil phase A is slightly lower than that of the water phase B, stirring continuously, adding the borneol serving as the main drug C when the matrix starts to emulsify, and continuously stirring until the mixture is completely emulsified;
(2) cooling matrix to room temperature, adding Realgar as principal agent C for 3 times, and stirring.
Prescription and treatment effect evaluation: the compound realgar ointment prepared by the prescription has good stability, but has larger viscosity, poor spreadability and poor skin adhesiveness; the clinical use effect is better, and the patient acceptance is low.
Example 7:
a compound realgar ointment for treating herpes zoster and a preparation method thereof, the preparation method comprises the following steps:
the composite material comprises the following raw materials in percentage by weight:
a oil phase
B aqueous phase
Principal drug C
10 percent of realgar
1 percent of borneol.
(1) Preparing a matrix: placing the oil phase A and the water phase B in a water bath at 90 ℃ until the oil phase A and the water phase B are completely dissolved, taking out the oil phase A, slowly pouring the water phase B into the oil phase A when the temperature of the oil phase A is slightly lower than that of the water phase B, stirring continuously, adding the borneol serving as the main drug C when the matrix starts to emulsify, and continuously stirring until the mixture is completely emulsified;
(2) cooling matrix to room temperature, adding Realgar as principal agent C for 3 times, and stirring.
Prescription and treatment effect evaluation: the compound realgar ointment prepared by the prescription has good stability, low viscosity, good spreadability and good skin adhesiveness; the clinical use effect is poor, and the patient acceptance is low.
Example 8:
a compound realgar ointment for treating herpes zoster and a preparation method thereof, the preparation method comprises the following steps:
the composite material comprises the following raw materials in percentage by weight:
a oil phase
B aqueous phase
Principal drug C
10 percent of realgar
1 percent of borneol.
(1) Preparing a matrix: placing the oil phase A and the water phase B in a water bath at 90 ℃ until the oil phase A and the water phase B are completely dissolved, taking out the oil phase A, slowly pouring the water phase B into the oil phase A when the temperature of the oil phase A is slightly lower than that of the water phase B, stirring continuously, adding the borneol serving as the main drug C when the matrix starts to emulsify, and continuously stirring until the mixture is completely emulsified;
(2) cooling matrix to room temperature, adding Realgar as principal agent C for 3 times, and stirring.
Prescription and treatment effect evaluation: the compound realgar ointment matrix prepared by the prescription has good stability, proper viscosity, good spreadability and poor skin adhesiveness; the clinical use effect is poor, and the patient acceptance is low.
Finally, the above embodiments are only used for illustrating the technical solutions of the present invention and not for limiting, although the present invention has been described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that modifications or equivalent substitutions may be made to the technical solutions of the present invention without departing from the spirit and scope of the technical solutions of the present invention, and all the technical solutions of the present invention should be covered in the claims of the present invention.
Claims (10)
1. A compound realgar ointment for treating herpes zoster is characterized in that the compound realgar ointment is an oil-in-water type cream and consists of an oil phase, a water phase and a main drug; the oil phase contains a surfactant, glyceryl monostearate; the water phase contains herba Taraxaci extract, herba Portulacae extract, tween 80 and poloxamer 188; the main drugs are realgar and borneol.
2. The compound realgar ointment of claim 1, wherein the oil phase accounts for 35-50% of the compound realgar ointment, the water phase accounts for 40-60% of the compound realgar ointment, and the main drug accounts for 5-20% of the compound realgar ointment;
preferably, the oil phase accounts for 40-45% of the compound realgar ointment, the water phase accounts for 45-55% of the compound realgar ointment, and the main drug accounts for 10-15% of the compound realgar ointment.
3. The compound realgar ointment of claim 1, wherein in the compound realgar ointment, the weight percentage content of the glyceryl monostearate is 1.0-4.0%, the weight percentage content of the dandelion extract is 0.5-2.5%, the weight percentage content of the purslane extract is 0.5-2.5%, the weight percentage content of the tween 80 is 2.0-5.0%, the weight percentage content of the poloxamer 188 is 0.1-1.0%, the weight percentage content of the realgar is 5.0-15.0%, and the weight percentage content of the borneol is 0.5-1.5%;
preferably, the weight percentage content of the glyceryl monostearate is 2.0-3.0%, the weight percentage content of the dandelion extract is 1.0-2.0%, the weight percentage content of the purslane extract is 1.0-2.0%, the weight percentage content of the tween 80 is 3.0-4.0%, the weight percentage content of the poloxamer 188 is 0.2-0.5%, the weight percentage content of the realgar is 8.0-12.0%, and the weight percentage content of the borneol is 0.8-1.2%.
4. The compound realgar ointment of claim 1, wherein the compound realgar ointment is composed of an oil phase, a water phase and a main drug; the oil phase contains vaseline, liquid paraffin, cetyl alcohol, stearyl alcohol, glyceryl monostearate and Azone (oil soluble laurocapram); the water phase contains herba Taraxaci extract, herba Portulacae extract, glycerol, Tween 80, poloxamer 188 and ethylparaben; the main drugs are realgar and borneol.
5. The compound realgar ointment according to claim 4, wherein in the compound realgar ointment, the weight percentage of vaseline is 5.0% -15.0%, the weight percentage of liquid paraffin is 10.0% -20.0%, the weight percentage of hexadecanol is 5.0% -15.0%, the weight percentage of octadecanol is 5.0% -15.0%, the weight percentage of glyceryl monostearate is 1.0% -4.0%, and the weight percentage of Azone (oil-soluble laurocapram) is 0.5% -2.5%; the weight percentage content of the dandelion extract is 0.5-2.5%, the weight percentage content of the purslane extract is 0.5-2.5%, the weight percentage content of the glycerol is 1.5-10.0%, the weight percentage content of the tween 80 is 2.0-5.0%, the weight percentage content of the poloxamer 188 is 0.1-1.0%, and the weight percentage content of the ethylparaben is 0-0.5%; the weight percentage content of the realgar is 5.0 to 15.0 percent, and the weight percentage content of the borneol is 0.5 to 1.5 percent;
preferably, in the compound realgar ointment, the weight percentage of the vaseline is 7.0-12.0%, the weight percentage of the liquid paraffin is 12.0-15.0%, the weight percentage of the hexadecanol is 8.0-12.0%, the weight percentage of the octadecanol is 8.0-12.0%, the weight percentage of the glyceryl monostearate is 2.0-3.0%, and the weight percentage of the Azone (oil-soluble laurocapram) is 1.0-2.0%; 1.0-2.0% of dandelion extract, 1.0-2.0% of purslane extract, 2.5-5.0% of glycerol, 3.0-4.0% of tween 80, 0.2-0.5% of poloxamer 188 and 0.1-0.3% of ethylparaben; the weight percentage content of the realgar is 8.0-12.0 percent, and the weight percentage content of the borneol is 0.8-1.2 percent.
6. The compound realgar ointment of claim 4, comprising the following raw materials in percentage by weight:
a oil phase
B aqueous phase
Principal drug C
10 percent of realgar
1 percent of borneol.
7. The method for preparing the compound realgar ointment according to any one of claims 1 to 6, which comprises the step of preparing the compound realgar ointment from the oil phase, the water phase and the main drug by a high-speed shearing method.
8. The method of claim 7, comprising the steps of:
(1) preparing a matrix: placing the oil phase A and the water phase B in a water bath at 90 ℃ until the oil phase A and the water phase B are completely dissolved, taking out the oil phase C, slowly pouring the water phase into the oil phase when the temperature of the oil phase is slightly lower than that of the water phase, stirring continuously, adding borneol when the substrate starts to be emulsified, and continuously stirring until the mixture is completely emulsified;
(2) cooling matrix to room temperature, adding Realgar by 3 times, and stirring.
9. The method for preparing compound realgar ointment according to any one of claims 7 to 8, wherein the dandelion extract is prepared by the following steps: taking 200g of dandelion, adding 800g of water, and decocting with slow fire to 200 mL.
The purslane extracting solution is prepared by a decocting method: 200g of purslane is taken, 800g of water is added, and the mixture is decocted to 200mL by slow fire.
10. The use of the compound realgar ointment according to any one of claims 1 to 6 in the preparation of a medicament for killing herpes zoster virus and treating herpes zoster.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110763769.9A CN113318072A (en) | 2021-07-06 | 2021-07-06 | Compound realgar ointment for treating herpes zoster and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110763769.9A CN113318072A (en) | 2021-07-06 | 2021-07-06 | Compound realgar ointment for treating herpes zoster and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113318072A true CN113318072A (en) | 2021-08-31 |
Family
ID=77425866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110763769.9A Pending CN113318072A (en) | 2021-07-06 | 2021-07-06 | Compound realgar ointment for treating herpes zoster and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113318072A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107510708A (en) * | 2017-08-29 | 2017-12-26 | 宁波保税区攀峒信息科技有限公司 | A kind of purslane dandelion Eradicates rash cream and usage food ointment chemical product physiotherapy cream |
-
2021
- 2021-07-06 CN CN202110763769.9A patent/CN113318072A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107510708A (en) * | 2017-08-29 | 2017-12-26 | 宁波保税区攀峒信息科技有限公司 | A kind of purslane dandelion Eradicates rash cream and usage food ointment chemical product physiotherapy cream |
Non-Patent Citations (3)
| Title |
|---|
| 尚树莉等: "马蒲合剂外用治疗带状疱疹16例", 《陕西中医函授》 * |
| 欧广升: "《敷贴不求人》", 31 May 2010, 湖南科学技术出版社 * |
| 部娜等: "星点设计-效应面法优化雄黄乳膏剂的处方组成", 《中成药》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6027728A (en) | Herbal skin regeneration composition and method | |
| CN109700720B (en) | Infant care cream and preparation method thereof | |
| CN103169928A (en) | Externally applied traditional Chinese medicine composition for treating dysmenorrhea, as well as preparation method and application thereof | |
| CN108815435A (en) | A kind of preparation method of the Chinese medicine composition for treating pruritus dermatopathy and its preparation | |
| EP3821902B1 (en) | Traditional chinese medicine composition, traditional chinese medicine compound preparation and preparation method and use thereof | |
| CN1326546C (en) | Pure Chinese medicinal preparation for external treating burn and scald | |
| CN113209238A (en) | Lotion for treating hand-foot syndrome caused by targeted medicament and preparation method thereof | |
| CN113398237A (en) | Traditional Chinese medicine composition with antibacterial, itching relieving and dandruff stopping functions and preparation method thereof | |
| CN104873446A (en) | Cinnamon oil containing toothpaste | |
| CN104825941B (en) | A kind of herbal composite and preparation method thereof for treating tinea pedis | |
| CN104906466B (en) | A kind of folium eucalypti emulsifiable paste and preparation method thereof | |
| CN110652552A (en) | Wound healing formula and preparation method | |
| CN106822321B (en) | Application of Curcuma water of traumatology in preparing medicine for treating keratosis pilaris | |
| CN105663928A (en) | Ointment for treating skin diseases of animals as well as preparation method of ointment | |
| CN101987135B (en) | Medicine for treating tetanus and preparation method thereof | |
| CN113318072A (en) | Compound realgar ointment for treating herpes zoster and preparation method thereof | |
| CN113797250B (en) | External traditional Chinese medicine composition and preparation method and application thereof | |
| CN109432211B (en) | Traditional Chinese medicine composition for psoriasis and eczema, external medicine thereof, and preparation methods and application of traditional Chinese medicine composition and external medicine | |
| CN108721442B (en) | Traditional Chinese medicine composition and preparation for treating burns, scalds and diaper dermatitis and preparation method thereof | |
| CN101940652B (en) | Chinese medicinal liniment for treating psoriasis, multiple kinds of stubborn dermatitis and pruritus | |
| CN112755101B (en) | Traditional Chinese medicine composition for treating knee osteoarthritis and application thereof | |
| CN115429859B (en) | Traditional Chinese medicine composition for treating skin itch diseases and preparation method and application thereof | |
| CN107050126A (en) | Chinese drugs agentia for treating acne | |
| CN115414423B (en) | Traditional Chinese medicine composition for treating eczema and application of traditional Chinese medicine composition in preparation of itching-relieving and healing-promoting cream | |
| CN116115687B (en) | Traditional Chinese medicine composition for gout and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210831 |